Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
2024年3月27日 - 12:06AM
Further to the announcement by Psyence Group Inc
("
Psyence" or the "
Company")
(CSE:PSYG) of its plans for the strategic restructuring of its
non-clinical business through a conditional M&A transaction
(the "
Transaction"), Psyence is pleased to
announce that the conditions to implement the Transaction have been
met and that the Transaction has closed.
Psyence has built a network of potential clients
and customers, and successfully and lawfully distributed psilocybin
internationally, both itself and via its strategic partners.
Psyence plans to leverage its experience and expertise in the
sector to build a pipeline of business, a route-to-market, as well
as a lawful and fully licensed distribution network and logistics
plan for the distribution of psilocybin globally. Psyence will play
a vital role in ensuring the commercial success of the Transaction
target non-clinical assets and business and will continue exploring
new markets for medical grade psilocybin and active pharmaceutical
ingredients.
FORWARD LOOKING STATEMENTS:
Certain statements in this news
release related to Psyence Group Inc and its subsidiaries
(collectively the "Company") are forward-looking
statements and are prospective in nature. Forward-looking
statements are not based on historical facts, but rather on current
expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied
by the forward-looking statements. These statements generally
can be identified by the use of forward-looking words such as
"may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe" or "continue", or the negative
thereof or similar variations. Forward-looking statements in this
news release include statements regarding the successful
development and commercialisation of products and services from the
Transaction target non-clinical assets and businesses and Psyence's
ability to build a pipeline of business for such products and
services. These forward-looking statements are based on a number of
assumptions, including the assumptions that fund raising efforts
will yield favourable results to attract sufficient private
investment to realise strategic goals. There are numerous risks and
uncertainties that could cause actual results and the Company’s
plans and objectives to differ materially from those expressed in
the forward-looking information. These risks and uncertainties
include not raising sufficient private investment to execute
business objectives and that the products developed will not find
commercial success in the global medical, R&D and OTC markets.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on
estimates and opinions of management on the dates they are made and
are expressly qualified in their entirety by this notice. Except as
required by law, the Company does not intend to update
these forward-looking statements.
The Company makes no medical, treatment or
health benefit claims about the Company’s proposed products. The
U.S. Food and Drug Administration, Health Canada or other similar
regulatory authorities have not evaluated claims regarding
psilocybin, psilocybin analogues, or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psilocybin analogues, or other psychedelic compounds
or nutraceuticals can diagnose, treat, cure or prevent any disease
or condition. Vigorous scientific research and clinical trials are
needed. The Company has not conducted clinical trials for the use
of its proposed products. Any references to quality, consistency,
efficacy, and safety of potential products do not imply that the
Company verified such in clinical trials or that the Company will
complete such trials. If the Company cannot obtain the approvals or
research necessary to commercialize its business, it may have a
material adverse effect on the Company’s performance and
operations.
Contact Information
Email: ir@psyence.comMedia Inquiries:
media@psyence.comGeneral Information: info@psyence.comPhone:
+1 416-477-1708
ABOUT PSYENCE
GROUP: www.psyence.com
Psyence is a life science biotechnology company
listed on the Canadian Securities Exchange (CSE:PSYG), with a focus
on natural psychedelics. Psyence works with nature-derived
psilocybin products for the healing of psychological trauma and its
mental health consequences in the context of palliative care. Our
name "Psyence" combines the
words psychedelic and science to affirm our
commitment to producing psychedelic medicines developed through
evidence-based research. Informed by nature
and guided by science, we built and operate one of the world’s
first federally licensed commercial psilocybin mushroom cultivation
and production facilities in Southern Africa. Our team brings
international experience in both business and science and includes
experts in mycology, neurology, palliative care, and drug
development. We work to develop advanced nature-derived
psilocybin products for clinical research and development.
Our divisions, Psyence Production and Psyence
Function anchor an international collaboration, with operations in
Canada, the United Kingdom, and Southern Africa, and a presence in
the United States and Australia.
Learn more at www.psyence.com and on Twitter,
Instagram and LinkedIn.
Psyence Biomedical (NASDAQ:PBM)
過去 株価チャート
から 9 2024 まで 10 2024
Psyence Biomedical (NASDAQ:PBM)
過去 株価チャート
から 10 2023 まで 10 2024